JP7084881B2 - Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 - Google Patents

Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 Download PDF

Info

Publication number
JP7084881B2
JP7084881B2 JP2018566552A JP2018566552A JP7084881B2 JP 7084881 B2 JP7084881 B2 JP 7084881B2 JP 2018566552 A JP2018566552 A JP 2018566552A JP 2018566552 A JP2018566552 A JP 2018566552A JP 7084881 B2 JP7084881 B2 JP 7084881B2
Authority
JP
Japan
Prior art keywords
scil
amino acid
polypeptide
linker
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018566552A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527200A5 (cg-RX-API-DMAC7.html
JP2019527200A (ja
Inventor
ムスターカス、ディミトリ、ティー．
ナムチュク、マーク、エヌ．
ロージー、ヘザー、シー．
アルバレス、ファン、シー．
Original Assignee
アルカームス インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アルカームス インコーポレーテッド filed Critical アルカームス インコーポレーテッド
Publication of JP2019527200A publication Critical patent/JP2019527200A/ja
Publication of JP2019527200A5 publication Critical patent/JP2019527200A5/ja
Application granted granted Critical
Publication of JP7084881B2 publication Critical patent/JP7084881B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2018566552A 2016-06-22 2017-06-22 Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法 Active JP7084881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353478P 2016-06-22 2016-06-22
US62/353,478 2016-06-22
PCT/US2017/038747 WO2018005226A2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Publications (3)

Publication Number Publication Date
JP2019527200A JP2019527200A (ja) 2019-09-26
JP2019527200A5 JP2019527200A5 (cg-RX-API-DMAC7.html) 2020-07-30
JP7084881B2 true JP7084881B2 (ja) 2022-06-15

Family

ID=60674961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566552A Active JP7084881B2 (ja) 2016-06-22 2017-06-22 Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法

Country Status (6)

Country Link
US (2) US10335459B2 (cg-RX-API-DMAC7.html)
EP (1) EP3474884A4 (cg-RX-API-DMAC7.html)
JP (1) JP7084881B2 (cg-RX-API-DMAC7.html)
AU (2) AU2017291321B2 (cg-RX-API-DMAC7.html)
CA (1) CA3026393C (cg-RX-API-DMAC7.html)
WO (1) WO2018005226A2 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
CA2848656C (en) 2010-09-15 2017-10-10 Randall J. Mrsny Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
ES2900328T3 (es) 2014-05-07 2022-03-16 Applied Molecular Transport Inc Moléculas de fusión derivadas de toxina Cholix para la administración oral de carga biológicamente activa
EP3233920B1 (en) * 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
US20210347843A9 (en) * 2018-03-23 2021-11-11 Gavish-Galilee Bio Applications Ltd. Genetically reprogrammed tregs expressing membrane-bound il-10
SG11202104721RA (en) 2018-11-07 2021-06-29 Applied Molecular Transport Inc Delivery constructs for transcytosis and related methods
US12006345B2 (en) 2019-02-21 2024-06-11 Xencor, Inc. Untargeted and targeted IL-10 Fc-fusion proteins
BR112022002962A2 (pt) 2019-08-16 2022-07-05 Applied Molecular Transport Inc Composições, formulações e produção e purificação de interleucina
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
DK4065585T3 (da) 2019-11-25 2025-09-08 Alkermes Inc Substituerede makrocykliske forbindelser og relaterede behandlingsfremgangsmåder
WO2021202885A1 (en) * 2020-04-03 2021-10-07 Baylor College Of Medicine TNFα SIGNALING TRIGGERS TUMOR-PROMOTING INFLAMMATION THAT CAN BE TARGETED TO THERAPY
US11673930B2 (en) 2020-05-12 2023-06-13 Regeneran Pharmaceuticals, Inc. IL10 agonists and methods of use thereof
CA3180304A1 (en) * 2020-05-28 2021-12-02 Kenan Christopher GARCIA Engineered interleukin-10 polypeptides and uses thereof
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
AU2024282178A1 (en) * 2023-06-02 2025-11-27 Synthekine, Inc. Fused il10 polypeptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Ｒｈａｍｍアンタゴニスト抗体
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
EP1200124B1 (en) 1999-07-13 2008-09-10 Bolder Biotechnology, Inc. Erythropoietin-immunoglobulin fusion proteins
EP1257574A1 (en) 2000-02-11 2002-11-20 Maxygen Aps Improved interleukin 10
AU2003280315A1 (en) * 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
CN102939303A (zh) 2009-12-22 2013-02-20 诺瓦提斯公司 四价cd47-抗体恒定区融合蛋白用于治疗
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
AU2011226992B2 (en) 2010-05-10 2012-03-22 Ascend Biopharmaceuticals Pty Ltd Immunostimulatory and vaccine compositions
CN101962413B (zh) 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
TWI743461B (zh) 2011-03-28 2021-10-21 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
EP3321286B1 (en) 2011-08-23 2021-01-06 Roche Glycart AG Bispecific t cell activating antigen binding molecules
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
EP3825405A1 (en) * 2012-06-08 2021-05-26 Alkermes Pharma Ireland Limited Ligands modified by circular permutation as agonists and antagonists
US20140072581A1 (en) 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
KR20150038012A (ko) * 2012-08-08 2015-04-08 로슈 글리카트 아게 인터루킨-10 융합 단백질 및 그의 용도
WO2014151910A1 (en) 2013-03-15 2014-09-25 Amgen Inc. Heterodimeric bispecific antibodies
CA2908208A1 (en) * 2013-04-24 2014-10-30 Armo Biosciences, Inc. Interleukin-10 compositions and uses thereof
WO2015017548A2 (en) * 2013-07-31 2015-02-05 Amgen Inc. Stabilization of fc-containing polypeptides
WO2015117930A1 (en) 2014-02-06 2015-08-13 F. Hoffmann-La Roche Ag Interleukine 10 immunoconjugates
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
EP3233920B1 (en) 2014-12-19 2020-08-26 Alkermes, Inc. Single chain fc fusion proteins
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
WO2018005226A2 (en) 2016-06-22 2018-01-04 Alkermes, Inc. Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130316404A1 (en) 2010-11-26 2013-11-28 The University Of Manchester Covalently linked interleukin-10

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J Biol Chem，2006年，Vol.281, No.46，pp.35088-35096
J Exp Med，2000年，Vol.191, No. 2，pp.213-223

Also Published As

Publication number Publication date
WO2018005226A2 (en) 2018-01-04
US10335459B2 (en) 2019-07-02
US20190336582A1 (en) 2019-11-07
AU2017291321B2 (en) 2020-06-18
NZ748787A (en) 2021-06-25
WO2018005226A3 (en) 2018-04-05
EP3474884A2 (en) 2019-05-01
EP3474884A4 (en) 2020-08-19
US20170368144A1 (en) 2017-12-28
CA3026393A1 (en) 2018-01-04
AU2017291321A1 (en) 2018-12-13
AU2020204457A1 (en) 2020-07-23
US11534480B2 (en) 2022-12-27
CA3026393C (en) 2023-03-14
JP2019527200A (ja) 2019-09-26

Similar Documents

Publication Publication Date Title
JP7084881B2 (ja) Ｉｌ－１０の免疫刺激特性および抗炎症特性を調節するための組成物および方法
US10881741B2 (en) Single chain Fc fusion proteins
US20240368236A1 (en) Growth differentiation factor 15 (gdf-15) constructs
ES2689762T3 (es) Proteínas de fusión para el tratamiento de trastornos metabólicos
JP7064618B2 (ja) 増殖分化因子１５アゴニスト化合物およびその使用方法
ES2966133T3 (es) Proteína de fusión que comprende el factor de crecimiento nervioso y método de preparación y uso de la misma
JP7013390B2 (ja) Ｍｉｃ－１化合物及びその使用
JP7058670B2 (ja) 増殖分化因子１５融合タンパク質
KR20210065057A (ko) 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
WO2022187488A2 (en) Mutant pd-1 extracellular domains
NZ748787B2 (en) Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties
HK1242337B (en) Single chain fc fusion proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210915

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211214

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220510

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220603

R150 Certificate of patent or registration of utility model

Ref document number: 7084881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150